Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2025)

Anaptysbio's Cash from Financing Activities history spans 10 years, with the latest figure at -$43.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 256.47% year-over-year to -$43.1 million; the TTM value through Dec 2025 reached -$132.6 million, down 204.38%, while the annual FY2025 figure was -$132.6 million, 204.38% down from the prior year.
  • Cash from Financing Activities reached -$43.1 million in Q4 2025 per ANAB's latest filing, down from -$10.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $251.3 million in Q4 2021 to a low of -$50.5 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $11.6 million, with a median of $204000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 199373.02% in 2021, then plummeted 3223.15% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $251.3 million in 2021, then crashed by 99.22% to $1.9 million in 2022, then tumbled by 364.7% to -$5.2 million in 2023, then skyrocketed by 634.35% to $27.6 million in 2024, then tumbled by 256.47% to -$43.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Cash from Financing Activities are -$43.1 million (Q4 2025), -$10.4 million (Q3 2025), and -$50.5 million (Q2 2025).